In their study, the serum HMGB1 levels were higher in COPD patients with more severe airflow limitation (mean %FEV1, 49%) when compared with the results in the present study, and they found that patients with lung cancer had even higher levels of serum HMGB1. The gene discussed is HMGB1; the disease is chronic obstructive pulmonary disease.